Clinical trials: Recurrent Osteosarcoma
Metastatic Melanoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas
This phase I/II trial studies the side effects and best dose of nivolumab when given with or without ipilimumab to see how well they work in treating younger patients with solid tumors or sarcomas that have come back (recurrent)…
- Conditions
- Metastatic Melanoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Hodgkin Lymphoma, Recurrent Malignant Solid Neoplasm
- Trial name
- NCT02304458
- Testing
- Ipilimumab, Laboratory Biomarker Analysis, Nivolumab
- Where
- 25 sites in United States, Canada
- Volunteers
- 140 people
- Sponsor
- National Cancer Institute (NCI)
Adult Liposarcoma, Metastatic Liposarcoma
Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas
The purpose of this clinical research study is to learn if pazopanib when given in combination with topotecan can help to control sarcomas. The safety of this drug combination will also be studied.
- Conditions
- Adult Liposarcoma, Metastatic Liposarcoma, Metastatic Osteosarcoma, Recurrent Adult Soft Tissue Sarcoma
- Trial name
- NCT02357810
- Testing
- Pazopanib Hydrochloride, Oral Topotecan Hydrochloride, Laboratory Biomarker Analysis
- Where
- 8 sites in United States
- Volunteers
- 178 people
- Sponsor
- Northwestern University
Recurrent Osteosarcoma
Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma
This phase II trial studies how well glembatumumab vedotin works in treating patients with osteosarcoma that has come back (recurrent) or does not respond to treatment (refractory).
- Trial name
- NCT02487979
- Testing
- Glembatumumab Vedotin, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 155 sites in United States, Canada and 1 more
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma
Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma
This randomized phase II trial studies how well gemcitabine hydrochloride works with or without pazopanib hydrochloride in treating patients with refractory soft tissue sarcoma.
- Conditions
- Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma, Adult Desmoplastic Small Round Cell Tumor, Adult Epithelioid Hemangioendothelioma
- Trial name
- NCT01532687
- Testing
- Gemcitabine, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- OHSU Knight Cancer Institute
Childhood Choroid Plexus Tumor, Childhood Medulloblastoma
Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer
This randomized phase III trial studies flexible administration of filgrastim after combination chemotherapy to see how well it works compared to fixed administration of filgrastim in decreasing side effects of chemotherapy in…
- Conditions
- Childhood Choroid Plexus Tumor, Childhood Medulloblastoma, Childhood Pineoblastoma, Childhood Soft Tissue Sarcoma
- Trial name
- NCT01987596
- Testing
- filgrastim
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Recurrent Osteosarcoma
Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma
This phase II trial studies how well eribulin mesylate works in treating patients with osteosarcoma that has come back after treatment (recurrent) or has not responded to treatment (refractory).
- Trial name
- NCT02097238
- Testing
- Eribulin Mesylate, Pharmacological Study
- Where
- 119 sites in United States, Canada
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Hepatoblastoma, Previously Treated Childhood Rhabdomyosarcoma
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
This phase II trial is studying the side effects of and how well alisertib works in treating young patients with relapsed or refractory solid tumors or leukemia.
- Conditions
- Hepatoblastoma, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia
- Trial name
- NCT01154816
- Testing
- Alisertib, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 105 sites in United States, Canada
- Volunteers
- 118 people
- Sponsor
- Children's Oncology Group
Childhood Alveolar Soft Part Sarcoma, Childhood Angiosarcoma
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
This phase II trial studies how well cixutumumab and temsirolimus work in treating patients with recurrent or refractory sarcoma. Monoclonal antibodies, such as cixutumumab, can block tumor growth in different ways.
- Conditions
- Childhood Alveolar Soft Part Sarcoma, Childhood Angiosarcoma, Childhood Epithelioid Sarcoma, Childhood Fibrosarcoma
- Trial name
- NCT01614795
- Testing
- Cixutumumab, Laboratory Biomarker Analysis, Temsirolimus
- Where
- 76 sites in United States, Canada
- Volunteers
- 46 people
- Sponsor
- National Cancer Institute (NCI)
Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma
Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
This randomized phase I/II clinical trial is studying the side effects and best dose of gamma-secretase/notch signalling pathway inhibitor RO4929097 when given together with vismodegib and to see how well they work in treating…
- Conditions
- Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma, Adult Desmoplastic Small Round Cell Tumor, Adult Epithelioid Hemangioendothelioma
- Trial name
- NCT01154452
- Testing
- Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- National Cancer Institute (NCI)
Bone Cancer, Chondrosarcoma
Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery
This phase II trial studies how well therapeutic angiotensin-(1-7) works as second-line therapy or third-line therapy in treating patients with metastatic sarcoma that cannot be removed by surgery.
- Conditions
- Bone Cancer, Chondrosarcoma, Clear Cell Sarcoma of the Kidney, Metastatic Osteosarcoma
- Trial name
- NCT01553539
- Testing
- therapeutic angiotensin-(1-7), laboratory biomarker analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Wake Forest University Health Sciences
Adult Alveolar Soft-part Sarcoma, Adult Angiosarcoma
Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma
This phase II trial studies how well depsipeptide (romidepsin) works in treating patients with metastatic or unresectable soft tissue sarcoma.
- Conditions
- Adult Alveolar Soft-part Sarcoma, Adult Angiosarcoma, Adult Epithelioid Sarcoma, Adult Extraskeletal Chondrosarcoma
- Trial name
- NCT00112463
- Testing
- romidepsin
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Osteosarcoma, Recurrent Adult Soft Tissue Sarcoma
Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma
This phase II trial studies how well temsirolimus and cixutumumab works in treating patients with locally advanced, metastatic, or recurrent soft tissue sarcoma or bone sarcoma.
- Conditions
- Metastatic Osteosarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Osteosarcoma, Stage III Adult Soft Tissue Sarcoma
- Trial name
- NCT01016015
- Testing
- Cixutumumab, Laboratory Biomarker Analysis, Temsirolimus
- Where
- 24 sites in United States, Canada
- Volunteers
- 178 people
- Sponsor
- National Cancer Institute (NCI)
Adult Rhabdomyosarcoma, Adult Synovial Sarcoma
Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors
This phase II trial is studying the side effects and how well cixutumumab works in treating patients with relapsed or refractory solid tumors. Monoclonal antibodies, such as cixutumumab, can block tumor growth in different ways.
- Conditions
- Adult Rhabdomyosarcoma, Adult Synovial Sarcoma, Childhood Hepatoblastoma, Childhood Synovial Sarcoma
- Trial name
- NCT00831844
- Testing
- cixutumumab, laboratory biomarker analysis
- Where
- 105 sites in United States, Australia and 1 more
- Volunteers
- 116 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Metastatic Osteosarcoma
Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07)
This phase II trial is studying how well sorafenib works in treating patients with soft tissue sarcoma. Sorafenib may stop the growth of soft tissue sarcoma by blocking blood flow to the tumor and blocking some of the enzymes…
- Conditions
- Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Metastatic Osteosarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
- Trial name
- NCT00330421
- Testing
- sorafenib tosylate, therapeutic conventional surgery, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)